Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
1(50.0%)
N/A
1(50.0%)
2Total
Phase 2(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06114628Phase 2Recruiting

Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB

Role: collaborator

NCT02639936Completed

New Generation IGRA in Immunocompromised Individuals

Role: lead

NCT05202431Not ApplicableCompleted

The Effect of Telephone Follow-up and Training on Treatment Adherence in Tuberculosis Patients and Contacts

Role: lead

NCT00707317Completed

T Cell Interferon-gamma Release Assay (TIGRA) in Immunocompromised Individuals

Role: lead

All 4 trials loaded